Scholarlink

<p>Important new insights into the prevention and treatment of type&#xa0;2 diabetes are summarized. The focus is on pharmacological therapy in accordance with current national and international guidelines. In patients with high cardiovascular or renal risk, early pharmacological treatment with an SGLT2 (sodium-glucose cotransporter 2) inhibitor or a&#xa0;GLP‑1 (glucagon-like peptide-1) receptor agonist—both of which have demonstrated superiority in outcome trials—has become established. Particularly in the field of incretin-based therapies, development continues to advance. New dosages and various oral formulations are complementing existing treatment algorithms. For the dual GIP(glucose-dependent insulinotropic polypeptide)/GLP‑1 receptor agonist tirzepatide, the first representative of a&#xa0;new generation of designer molecules that exert their effects through multiple receptors in a&#xa0;targeted manner, outcome trial data are now available. Therapy with once-weekly injectable basal insulin is also being further developed, including a&#xa0;fixed combination with semaglutide, which may represent an alternative to daily injections for many patients with type&#xa0;2 diabetes. With regard to improving treatment safety and achieving more stable metabolic control, the use of automated insulin delivery (AID) systems—following the adoption of continuous glucose monitoring—could also gain significant importance in the management of type&#xa0;2 diabetes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Update Typ-2-Diabetes

  • 期刊论文

  • 发表日期：

    2026年6月30日

查看全文
  • Andreas Hamann

摘要

Important new insights into the prevention and treatment of type 2 diabetes are summarized. The focus is on pharmacological therapy in accordance with current national and international guidelines. In patients with high cardiovascular or renal risk, early pharmacological treatment with an SGLT2 (sodium-glucose cotransporter 2) inhibitor or a GLP‑1 (glucagon-like peptide-1) receptor agonist—both of which have demonstrated superiority in outcome trials—has become established. Particularly in the field of incretin-based therapies, development continues to advance. New dosages and various oral formulations are complementing existing treatment algorithms. For the dual GIP(glucose-dependent insulinotropic polypeptide)/GLP‑1 receptor agonist tirzepatide, the first representative of a new generation of designer molecules that exert their effects through multiple receptors in a targeted manner, outcome trial data are now available. Therapy with once-weekly injectable basal insulin is also being further developed, including a fixed combination with semaglutide, which may represent an alternative to daily injections for many patients with type 2 diabetes. With regard to improving treatment safety and achieving more stable metabolic control, the use of automated insulin delivery (AID) systems—following the adoption of continuous glucose monitoring—could also gain significant importance in the management of type 2 diabetes.